2023
Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis
Fu Z, Brooks M, Irvin S, Jordan S, Aben K, Anton-Culver H, Bandera E, Beckmann M, Berchuck A, Brooks-Wilson A, Chang-Claude J, Cook L, Cramer D, Cushing-Haugen K, Doherty J, Ekici A, Fasching P, Fortner R, Gayther S, Gentry-Maharaj A, Giles G, Goode E, Goodman M, Group A, Harris H, Hein A, Kaaks R, Kiemeney L, Köbel M, Kotsopoulos J, Kotsopoulos J, Le N, Lee A, Matsuo K, McGuire V, McLaughlin J, Menon U, Milne R, Moysich K, Pearce C, Pike M, Qin B, Ramus S, Riggan M, Rothstein J, Schildkraut J, Sieh W, Sutphen R, Terry K, Thompson P, Titus L, van Altena A, White E, Whittemore A, Wu A, Zheng W, Ziogas A, Taylor S, Tang L, Songer T, Wentzensen N, Webb P, Risch H, Modugno F. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis. Journal Of The National Cancer Institute 2023, 115: 539-551. PMID: 36688720, PMCID: PMC10165492, DOI: 10.1093/jnci/djad011.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerOral contraceptive useClear cell histotypeOvulatory yearsOvulation suppressionOdds ratioOvarian cancerContraceptive useNonmucinous epithelial ovarian cancerConfidence intervalsConsistent protective effectCase patientsMucinous tumorsPooled analysisProtective effectEOC riskControl participantsHistotypeCancerOvulationAssociationRegression modelsRiskYearsBeta coefficients
2016
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study
Kho PF, Fawcett J, Fritschi L, Risch H, Webb PM, Whiteman DC, Neale RE. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study. Cancer Causes & Control 2016, 27: 1457-1464. PMID: 27817122, DOI: 10.1007/s10552-016-0824-4.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsUse of NSAIDsPopulation-based case-control studyCase-control studyAnti-inflammatory drugsPancreatic cancerProtective effectHistory of NSAIDsUnconditional multivariable logistic regressionSelective COX-2 inhibitorsMultivariable logistic regressionPancreatic cancer riskSex-matched controlsCOX-2 inhibitorsPancreatic cancer studiesStatin useMedication useSmoking statusCancer riskMedication sectionStatinsCancerLogistic regressionMore frequent usersCancer studies
2013
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies
Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, Risch H, Wu AH, Webb PM, Moysich K, Doherty JA, Felberg A, Miller D, Jordan SJ, Study A, Group A, Goodman M, Lurie G, Chang-Claude J, Rudolph A, Kjær S, Jensen A, Høgdall E, Bandera E, Olson S, King M, Rodriguez-Rodriguez L, Kiemeney L, Marees T, Massuger L, van Altena A, Ness R, Cramer D, Pike M, Pearce C, Berchuck A, Schildkraut J, Whittemore A. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International Journal Of Epidemiology 2013, 42: 579-589. PMID: 23569193, PMCID: PMC3619957, DOI: 10.1093/ije/dyt042.Peer-Reviewed Original ResearchConceptsOvarian cancer subtypesCase-control studyTubal ligationCancer subtypesHistological typeOvarian cancerClear cellsProtective effectPopulation-based case-control studyFull-term birthOvarian cancer riskPooled odds ratioConditional logistic regressionRace/ethnicitySerous cancerMucinous tumorsBorderline tumorsControl womenHistological subtypesInvasive casesPooled analysisOdds ratioCancer riskDistinct etiologiesInternational collaborative study
1994
Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada)
Risch H, Jain M, Marrett L, Howe G. Dietary lactose intake, lactose intolerance, and the risk of epithelial ovarian cancer in southern Ontario (Canada). Cancer Causes & Control 1994, 5: 540-548. PMID: 7827241, DOI: 10.1007/bf01831382.Peer-Reviewed Original ResearchConceptsOral contraceptive useOvarian cancerContraceptive useLactose intoleranceTotal daily caloric intakeFull-term pregnancyEpithelial ovarian cancerCase-control studyDaily caloric intakeQuantitative diet historyDietary factorsLactose intakeCaloric intakeProtective effectDiet historyAge groupsCancerDaily consumptionIntoleranceIntakeTotal durationIntake valuesPopulation controlsRiskMore evidence